GlaxoSmithKline
π¬π§United Kingdom
- Country
- π¬π§United Kingdom
- Ownership
- Public
- Established
- 1929-01-01
- Employees
- 70.2K
- Market Cap
- $90B
- Website
- http://www.gsk.com
- Introduction
GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.
To Study Device Attributes by Investigating Errors Made in Use, Ease of Use and Preference Among Different Inhalers in Subjects With Asthma
Phase 4
Completed
- Conditions
- Asthma
- Interventions
- Device: ELLIPTADevice: MDIDevice: TURBUHALERDevice: DISKUS/ACCUHALER
- First Posted Date
- 2014-07-21
- Last Posted Date
- 2015-11-23
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 162
- Registration Number
- NCT02195284
- Locations
- π¬π§
GSK Investigational Site, Southampton, United Kingdom
A First in Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of a Intravenous (IV) Dose of GSK2831781 in Healthy Volunteers and Patients With Plaque Psoriasis
Phase 1
Completed
- Conditions
- Psoriasis
- Interventions
- Biological: GSK2831781Biological: Placebo
- First Posted Date
- 2014-07-21
- Last Posted Date
- 2021-03-25
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 67
- Registration Number
- NCT02195349
- Locations
- π¬π§
GSK Investigational Site, London, United Kingdom
Tenofovir Disoproxil Fumarate (TDF) 300mg 3 Years RD Therapy Chinese Chronic Hepatitis B (CHN) CHB Multiple Nucleos(t)Ide Analogues (NAs) Failure Points Pts PH4 PMS Study
- First Posted Date
- 2014-07-21
- Last Posted Date
- 2019-11-04
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 213
- Registration Number
- NCT02195518
- Locations
- π¨π³
GSK Investigational Site, Zhengzhou, China
Study to Evaluate the Efficacy, Safety and Tolerability of Bupropion Hydrochloride Extended-release Tablet, and Escitalopram Oxalate Capsule in Subjects With Major Depressive Disorder
Phase 3
Completed
- Conditions
- Depressive Disorder, Major
- Interventions
- First Posted Date
- 2014-07-16
- Last Posted Date
- 2020-02-25
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 534
- Registration Number
- NCT02191397
- Locations
- π¨π³
GSK Investigational Site, Wuhan, China
A Safety Study to Investigate the Skin Sensitization Potential of MFC51123
Phase 1
Completed
- Conditions
- Pain
- Interventions
- First Posted Date
- 2014-07-16
- Last Posted Date
- 2017-06-28
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 227
- Registration Number
- NCT02192203
- Locations
- πΊπΈ
TKL Research Inc, Paramus, New Jersey, United States
A Study to Evaluate the Pharmacokinetics of a Single Dose of Tafenoquine Co-administered With Either Artemether + Lumefantrine or Dihydroartemisinin + Piperaquine Tetraphosphate
Phase 1
Completed
- Conditions
- Malaria, Vivax
- Interventions
- First Posted Date
- 2014-07-09
- Last Posted Date
- 2017-07-13
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 120
- Registration Number
- NCT02184637
- Locations
- πΊπΈ
GSK Investigational Site, Baltimore, Maryland, United States
Safety and Immunogenicity Study of GlaxoSmithKline (GSK) Biologicals' Measles, Mumps and Rubella (MMR) Vaccine (209762) Compared to Merck & Co., Inc.'s MMR Vaccine in Healthy Children 12 to 15 Months of Age
Phase 3
Completed
- Conditions
- Measles; Mumps; RubellaMeasles-Mumps-Rubella Vaccine
- Interventions
- Biological: PriorixBiological: M-M-R IIBiological: VarivaxBiological: HavrixBiological: Prevnar 13
- First Posted Date
- 2014-07-09
- Last Posted Date
- 2021-01-07
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 1742
- Registration Number
- NCT02184572
- Locations
- π¨π³
GSK Investigational Site, Taoyuan, Taiwan
Comparative Bioavailability of Two Fixed Dose Combination (FDC) Formulations of Dutasteride and Tamsulosin Hydrochloride Relative to Co-administration of Dutasteride With Tamsulosin Hydrochloride in Healthy Male Subjects Under Fed and Fasted States
Phase 1
Completed
- Conditions
- Prostatic Hyperplasia
- Interventions
- Drug: Treatment sequence ADrug: Treatment sequence BDrug: Treatment sequence C
- First Posted Date
- 2014-07-09
- Last Posted Date
- 2018-06-19
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 84
- Registration Number
- NCT02184585
- Locations
- πΊπΈ
GSK Investigational Site, Baltimore, Maryland, United States
Study of Inhaler Device Attributes Investigating Critical and Overall Errors, Ease of Use, and Preference Between a Number of Inhaler Devices
Phase 4
Completed
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- Device: ELLIPTADevice: TURBUHALERDevice: DISKUS/ACCUHALERDevice: MDIDevice: HANDIHALERDevice: BREEZEHALER
- First Posted Date
- 2014-07-09
- Last Posted Date
- 2017-05-23
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 569
- Registration Number
- NCT02184624
- Locations
- π¬π§
GSK Investigational Site, Southampton, United Kingdom
A 24 Week Efficacy Study of Inhaled Umeclidinium (UMEC) in Patients of Chronic Obstructive Pulmonary Disease (COPD) Using a Novel Dry Powder Inhaler (NDPI)
Phase 3
Completed
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- Drug: Umeclidinium bromideDrug: Placebo
- First Posted Date
- 2014-07-09
- Last Posted Date
- 2020-06-29
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 308
- Registration Number
- NCT02184611
- Locations
- π°π·
GSK Investigational Site, Suwon, Korea, Republic of
Β© Copyright 2025. All Rights Reserved by MedPath